A new Belgian company has been launched to develop therapies for cognitive disorders using intellectual property from UCB SA. The company has received Series A financing of €17 million from a syndicate of Belgian and international investors. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
